A Combined Phase 1/2a, Exploratory Study of a Therapeutic Vaccine Using an Adenovirus Type 26 Vector Prime and Modified Vaccinia Ankara Boost Combination With Mosaic Inserts in HIV-1 Infected Adults Who Initiated Antiretroviral Treatment During Acute HIV Infection

The purpose of the study is to assess: 1 safety and tolerability of adenovirus serotype 26 (Ad26) prime and Modified Vaccinia Ankara (MVA) boost versus placebo in participants on suppressive antiretroviral therapy (ART) that was initiated during acute Human Immunodeficiency Virus (HIV) infection; 2) Measure the frequency and duration of sustained viremic control after receiving Ad26 prime/MVA boost or placebo, defined as greater than 24 weeks with plasma HIV ribonucleic acid (RNA) lesser than (<)50 copies/ml after antiretroviral (ARV) analytical treatment interruption (ATI).

Start Date01 Sep 2016

Sponsor / Collaborator

Janssen Vaccines & Prevention BV

NCT02788045

/ CompletedPhase 1/2

A Randomized, Parallel-Group, Placebo-Controlled, Double-Blind Phase 1/2a Study in Healthy HIV Uninfected Adults to Assess the Safety/Tolerability and Immunogenicity of 2 Different Prime/Boost Regimens; Priming With Trivalent Ad26.Mos.HIV and Boosting With Trivalent Ad26.Mos.HIV And Clade C Gp140 Plus Adjuvant or Priming With Tetravalent Ad26.Mos4.HIV and Boosting With Tetravalent Ad26.Mos4.HIV and Clade C Gp140 Plus Adjuvant

The purpose of this study is to assess the safety/tolerability of the 2 different vaccine regimens of priming with trivalent Ad26.Mos.HIV and boosting with trivalent Ad26.Mos.HIV and Clade C gp140 plus adjuvant or priming with tetravalent Ad26.Mos4.HIV and boosting with Ad26.Mos4.HIV and Clade C glycoprotein (gp)140 plus adjuvant. Immune responses of the different vaccine schedules will be assessed.

Start Date08 Jul 2016

Sponsor / Collaborator

Janssen Vaccines & Prevention BV

NCT02685020

/ CompletedPhase 1

A Randomized, Parallel-group, Placebo-controlled, Double-blind Phase 1 Study in Healthy HIV-uninfected Adults to Evaluate Safety/Tolerability and Immunogenicity of Different Vaccine Schedules With Ad26.Mos.HIV and Clade C gp140

The primary purpose of this study is to assess safety, tolerability of the different vaccine schedules (different regimen durations and different number of dose administrations) with Ad26.Mos.HIV and Clade C Glycoprotein (gp) 140 and to assess Envelope (Env)-binding Antibody (Ab) responses of the different vaccine schedules.

Start Date28 Mar 2016

Sponsor / Collaborator

Janssen Vaccines & Prevention BV

100 Clinical Results associated with Ad26 Mos HIV trivalent vaccine(Janssen)

100 Translational Medicine associated with Ad26 Mos HIV trivalent vaccine(Janssen)

100 Patents (Medical) associated with Ad26 Mos HIV trivalent vaccine(Janssen)

100 Deals associated with Ad26 Mos HIV trivalent vaccine(Janssen)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
HIV Infections	Phase 2	United States	Janssen Vaccines & Prevention BV	22 Dec 2014
HIV Infections	Phase 2	Thailand	Janssen Vaccines & Prevention BV	22 Dec 2014
HIV Infections	Phase 2	South Africa	Janssen Vaccines & Prevention BV	22 Dec 2014
HIV Infections	Phase 2	Rwanda	Janssen Vaccines & Prevention BV	22 Dec 2014
HIV Infections	Phase 2	Uganda	Janssen Vaccines & Prevention BV	22 Dec 2014

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02788045 (TRAVERSE, CTgov)	Phase 1/2	-	201	Ad26.Mos4.HIV Vaccine (Tetravalent Ad26.Mos4.HIV Vaccine)	ebuoydqhlf(frczmefqxw) = njulcbkjuk cvtthxcsvo (bzemxhakwk, gpsytgotiy - boeykepbrb) View more	-	09 Jun 2023
				Ad26.Mos.HIV Vaccine (Trivalent Ad26.Mos.HIV Vaccine)	ebuoydqhlf(frczmefqxw) = yzohdvnbyn cvtthxcsvo (bzemxhakwk, xriuzixehi - tehywrtsdb) View more
NCT02919306 (CTgov)	Phase 1/2	HIV Infections	27	MVA-Mosaic+Ad26.Mos.HIV (Ad26.Mos.HIV Vaccine or MVA Mosaic Vaccine)	strpsnhjkm(mkkdiioulo) = yekxgxxkgo jxexdvlxct (tkpmvkpizn, wgauibklyb - qdorvrpflq) View more	-	11 Mar 2022
				Placebo (Placebo)	strpsnhjkm(mkkdiioulo) = vhwcugktog jxexdvlxct (tkpmvkpizn, bssxemsavk - gidqsdcoaq) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Ad26 Mos HIV trivalent vaccine(Janssen)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation